Inactive Instrument

Highlights LYSOGENE

Equities

LYS

FR0013233475

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lysogene Fails to Secure Takeover Bid Amid Reorganization	23-04-17	MT
Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study	22-11-18	CI
Lysogene S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-23	CI
Lysogene Provides Additional Update on Aavance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MMPS IIIA	22-07-07	CI
Lysogene S.A. Provides Clinical Update on AAvance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA At the 25Th Annual ASGCT Meeting	22-05-18	CI
Lysogene S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of Mpsiiia	22-02-24	CI
Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101	22-02-11	CI
Lysogene S.A. Provides Medical Update	22-02-07	CI
Lysogene Restores Global Commercial Rights of Rare Disease Treatment	22-01-13	MT
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights	22-01-13	CI
Lysogene Awards Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program	21-12-20	CI
Lysogene S.A. Reports Earnings Results for the First Half 2021	21-09-24	CI
Global markets live: Sanofi, Walt Disney, Roche, Flatexdegiro, KBC Group...	21-08-30
Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis	21-08-30	CI
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome	21-06-11	CI
Global markets live: Tesla, BT Group, GameStop, Alibaba, Boeing...	21-06-10
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis	21-06-09	CI
Lysogene Announces Phase 3 Gene Therapy Platform Company Targeting Central Nervous System Diseases	21-05-20	CI
Lysogene S.A. Reports Earnings Results for the Year Ended 31 December 2020	21-03-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LYSOGENE

Equities

LYS

FR0013233475

Highlights

Filters